You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK):聯營公司北京鋭業獲得新增投資方增資,加速產能擴張
格隆匯 08-19 12:20

格隆匯8月19日丨四環醫藥(00460.HK)宣佈,集團聯營公司北京鋭業製藥有限公司("北京鋭業")引入廣東冠潤股權投資合夥企業(有限合)和南靖惠及股權投資合企業(有限合)("兩位投資方")作為投資者進行增資。

根據協議,兩位投資方以現金增資方式對北京鋭業進行投資。此次增資結束後,北京鋭業的整體估值為人民幣29億元。集團所佔北京鋭業的股權比例為40.966%,兩位投資方共佔北京鋭業的股權比例為6.896%。北京鋭業目前具有非PVC粉液雙室袋即配型輸液("該劑型")領先技術。北京鋭業已經獲得該劑型頭孢他啶、頭孢呋辛、頭孢地嗪多個品種和規格的生產批件,並預計之後會陸續獲得其它涵蓋中國主流抗生素及其他一線用藥品種的生產批件。

此次增資的資金用於公司的正常運營需求,為後續擴大生產能力,降低生產成本以及後續研發投入及業務拓展提供進一步支持,積極推動了項目進程。此次增資,體現了投資方對北京鋭業雙室袋業務的認可,以及對頭孢他啶、頭孢呋辛、頭孢地嗪三個抗生素產品(根據IQVIACHPA數據庫每年銷售金額為人民幣101.11億元)廣闊市場前景的期待。未來,北京鋭業的產品將全權由四環醫藥集團進行全國銷售,同時推出的投資方將充分發揮其在市場準入方面的優勢,助力產品快速打開市場。集團相信北京鋭業會成為中國治療性粉液雙室袋輸液行業的領導型企業,滿足廣大患者的用藥需求,併為集團創造可觀的回報。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account